LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs Of Clinical Benefit

Santaris Pharma announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously treated cancer patients with advanced malignancies. EZN-2968 is being evaluated in patients with solid tumors and lymphoma.

More: continued here

Filed under: Cancer on June 5th, 2009